Risk factors associated with the development of oral mucositis in pediatric oncology patients: Systematic review and meta-analysis.

OBJECTIVES Oral mucositis (OM) is an acute toxicity related to cancer treatment. This systematic review aimed to identify potential risk factors associated with the development of OM in pediatric cancer patients. METHODS A search was performed in four electronic databases to identify studies that analyzed risk factors for OM in pediatric cancer patients. RESULTS Nineteen articles were included. The incidence of OM ranged from 20% to 80.4%. Chemotherapeutic agents were potential risk factors for OM in eight (42%) studies. Hematological, hepatic, and renal parameters were also considered in eight (42%) studies, while specific individual factors were reported in five (26.3%) studies. Baseline disease, oral microbiota, genetic profile, and biomarkers were reported in four (21.5%) studies each. Meta-analysis showed that groups submitted to high-risk chemotherapy for OM had a 2.79-fold increased risk of OM. CONCLUSIONS Identifying risk factors for OM is essential in order to allow individualized and early prevention treatment.

[1]  R. Roesler,et al.  Oral mucositis in childhood cancer patients receiving high-dose methotrexate: Prevalence, relationship with other toxicities, and methotrexate elimination. , 2020, International journal of paediatric dentistry.

[2]  N. Yarom,et al.  MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy , 2020, Cancer.

[3]  S. Sonis,et al.  Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action , 2020, Supportive Care in Cancer.

[4]  Luiz M. A. Lima-Filho,et al.  Severe Oral Mucositis in Pediatric Cancer Patients: Survival Analysis and Predictive Factors , 2020, International journal of environmental research and public health.

[5]  A. Villa,et al.  An update on pharmacotherapies in active development for the management of cancer regimen-associated oral mucositis , 2020, Expert opinion on pharmacotherapy.

[6]  P. Arany,et al.  Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. , 2019, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.

[7]  I. Ribeiro,et al.  Chemotherapy in Pediatric Oncology Patients and the Occurrence of Oral Mucositis , 2019, International journal of clinical pediatric dentistry.

[8]  S. Heil.  Genetics of high-dose methotrexate-induced oral mucositis: current perspectives. , 2019, Pharmacogenomics.

[9]  G. Weinstock,et al.  Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis , 2019, Microbiome.

[10]  C. Leles,et al.  Effect of photobiomodulation on the severity of oral mucositis and molecular changes in head and neck cancer patients undergoing radiotherapy: a study protocol for a cost-effectiveness randomized clinical trial , 2019, Trials.

[11]  Nesrin Nural,et al.  Incidence of and risk factors for development of oral mucositis in outpatients undergoing cancer chemotherapy , 2018, International journal of nursing practice.

[12]  F. Mazhari,et al.  Management of oral mucositis in pediatric patients receiving cancer therapy: A systematic review and meta‐analysis , 2018, Pediatric blood & cancer.

[13]  N. Magné,et al.  Pharmacological modulation of radiation-induced oral mucosal complications. , 2018, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[14]  F. Eduardo,et al.  Retrospective study of the digestive tract mucositis derived from myeloablative and non-myeloablative/reduced-intensity conditionings with busulfan in hematopoietic cell transplantation patient , 2018, Supportive Care in Cancer.

[15]  Samreen I. Ahmed,et al.  Principles of cancer treatment by chemotherapy , 2018, Surgery (Oxford).

[16]  Tae Won Kim,et al.  Methotrexate elimination and toxicity: MTHFR 677C>T polymorphism in patients with primary CNS lymphoma treated with high‐dose methotrexate , 2017, Hematological oncology.

[17]  T. Chen,et al.  The XRCC 1 DNA repair gene modifies the environmental risk of stomach cancer: a hospital-based matched case-control study , 2017, BMC Cancer.

[18]  R. Maranhão,et al.  Clinical experience with drug delivery systems as tools to decrease the toxicity of anticancer chemotherapeutic agents , 2017, Expert opinion on drug delivery.

[19]  T. Komori,et al.  Intensity and duration of neutropenia relates to the development of oral mucositis but not odontogenic infection during chemotherapy for hematological malignancy , 2017, PloS one.

[20]  Robert K. Yu,et al.  Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis , 2017, PloS one.

[21]  M. Zecca,et al.  Preliminary study in a new protocol for the treatment of oral mucositis in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) and chemotherapy (CT) , 2017, Lasers in Medical Science.

[22]  C. Pui,et al.  Preventing and Managing Toxicities of High-Dose Methotrexate , 2016, The oncologist.

[23]  W. Kremers,et al.  The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  H. Shin,et al.  Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma , 2016, Blood research.

[25]  A. Sparreboom,et al.  ABCC4 Is a Determinant of Cytarabine‐Induced Cytotoxicity and Myelosuppression , 2016, Clinical and translational science.

[26]  Lingyun Ji,et al.  Comparative Toxicity by Sex Among Children Treated for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group , 2015, Pediatric blood & cancer.

[27]  R. Warschkow,et al.  Frequency of Oral Mucositis and Local Virus Reactivation in Herpes Simplex Virus Seropositive Children with Myelosuppressive Therapy , 2015, Klinische Pädiatrie.

[28]  J. A. Yunes,et al.  Oral Mucositis in Pediatric Acute Lymphoblastic Leukemia Patients: Evaluation of Microbiological and Hematological Factors , 2015, Pediatric hematology and oncology.

[29]  Lei Chen,et al.  MDR1 C3435T polymorphism and childhood acute lymphoblastic leukemia susceptibility: an updated meta-analysis. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[30]  J. Epstein,et al.  Oral mucositis in paediatric patients after chemotherapy for cancer. , 2014, Hong Kong medical journal = Xianggang yi xue za zhi.

[31]  W. Tissing,et al.  Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia , 2014, The Pharmacogenomics Journal.

[32]  G. Lyman,et al.  Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. , 2014, Critical reviews in oncology/hematology.

[33]  Igor Henrique Morais Silva,et al.  Seroprevalence of herpes virus associated with the presence and severity of oral mucositis in children diagnosed with acute lymphoid leukemia. , 2014, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[34]  N. Hamerschlak,et al.  Cost‐effectiveness of the introduction of specialized oral care with laser therapy in hematopoietic stem cell transplantation , 2014, Hematological oncology.

[35]  R. Marwaha,et al.  HSV-1 as well as HSV-2 is frequent in oral mucosal lesions of children on chemotherapy , 2014, Supportive Care in Cancer.

[36]  M. Petruzzi,et al.  Clinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukaemia: a case–control study , 2013, International Journal of Oral Science.

[37]  T. Modéer,et al.  Pretherapeutic Plasma Pro- and Anti- Inflammatory Mediators Are Related to High Risk of Oral Mucositis in Pediatric Patients with Acute Leukemia: A Prospective Cohort Study , 2013, PloS one.

[38]  T. Celkan,et al.  DNA repair gene XPD and XRCC1 polymorphisms and the risk of febrile neutropenia and mucositis in children with leukemia and lymphoma. , 2012, Leukemia research.

[39]  D. Thompson,et al.  Incidence and risk factors of oral mucositis in paediatric and adolescent patients undergoing chemotherapy. , 2011, Oral oncology.

[40]  S. Sonis.  Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. , 2009, Oral oncology.

[41]  J. P. Lauris,et al.  Oral mucositis in acute lymphoblastic leukaemia: analysis of 169 paediatric patients. , 2008, Oral diseases.

[42]  D. Thompson,et al.  Risk factors for oral mucositis in children undergoing chemotherapy: a matched case-control study. , 2008, Oral oncology.

[43]  K. K. Cheng,et al.  Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer. , 2008, European journal of cancer care.

[44]  A. Maloney,et al.  Measurement of oral mucositis in children: a review of the literature , 2007, Supportive Care in Cancer.

[45]  A. Yaren,et al.  MDR1 C3435T polymorphism in patients with breast cancer. , 2007, Archives of medical research.

[46]  G. Campus,et al.  Risk factors for oral mucositis in paediatric oncology patients receiving alkylant chemotherapy , 2006, BMC oral health.

[47]  G. Lyman,et al.  Crawford J, Dale DC, Lyman GH. Chemotherapy‐induced neutropenia: risks, consequences, and new directions for its management. Cancer. (2004) 100(2):228–37. , 2004 .

[48]  S. Sonis.  The pathobiology of mucositis , 2004, Nature Reviews Cancer.

[49]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[50]  M. He,et al.  A systematic review and meta-analysis of the effect of low-level laser therapy (LLLT) on chemotherapy-induced oral mucositis in pediatric and young patients , 2017, European Journal of Pediatrics.

[51]  R. Everett.  HSV-1 biology and life cycle. , 2014, Methods in molecular biology.

[52]  Yongmin Tang,et al.  Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies , 2013, Cancer Chemotherapy and Pharmacology.

[53]  D. Moher,et al.  Preferred reporting items of systematic review and meta-analyses: the PRISMA statement , 2011 .